Brief: NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
19/05/2022 14:40
May 19 (Reuters) - NeuroMetrix Inc NURO.O :
* NEUROMETRIX REPORTS THAT QUELL® WEARABLE NEUROMODULATION
DEVICE
HAS RECEIVED FDA DE NOVO AUTHORIZATION AS FIRST
NON-PHARMACOLOGICAL TREATMENT FOR FIBROMYALGIA
Source text for Eikon: ID:nGNX5FRvnB
Further company coverage: NURO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroMetrix
See all newsBrief: Neurometrix To Be Acquired By Electrocore
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13